LONDON, June 8, 2017 /PRNewswire/ -- The European next-generation sequencing (NGS) services market is undergoing transformation
"Low-cost and quick turnaround have amplified NGS uptake as an alternative to traditional microarray, capillary electrophoresis (CE) and Sanger methods, propelling demand across industries such as human genetics, plant and animal biotech, agriculture, microbiome, food and drug safety, and forensics," noted Transformational Health Unmesh Lal, Program Manager Life Sciences. "To align with upcoming growth opportunities in research and clinical applications, NGS service companies are expanding service lines with specialised applications beyond pure sequencing. These include customised gene panels, Exome sequencing, ribonucleic acid (RNA) sequencing, chromatin immunoprecipitation sequencing (ChiPseq), and methylation sequencing (MethilSeq)."
European Next-generation Sequencing Services Market, Forecast to 2023, new research from Frost & Sullivan's Life Sciences Growth Partnership Service program, analyses the NGS services market potential, providing insights on key trends, drivers and their implications. NGS services are primarily driven by research, followed by applied market segments. The study covers NGS conducted with next-generation platforms, such as sequencing-by-synthesis, sequencing-by-ligation, and single-molecule sequencing.
Click here (http://frost.ly/1ns) to learn more about the European Next-generation Sequencing Services Market and to talk to us.
Several trends and developments bolster the European NGS services market:
"Stringent reimbursement policies guided by cost-containment models, a fragmented NGS value chain, and political and economic factors are, however, creating market volatility in the short term," noted Lal. "Further, advancement and consumerisation of portable, real-time sequencers may reduce dependence on service providers for small-scale project needs."
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion
European Next-generation Sequencing Services Market, Forecast to 2023MCE8-52
Contact:Jana SchönebornCorporate Communications – EuropeP: +49 (0)69 77033 43E: firstname.lastname@example.org
http://ww2.frost.comtwitter: @FS_HealthcareLinkedIn: Transform Health
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/european-ngs-service-providers-prepare-to-leverage-growing-demand-for-exome-and-rna-sequencing-300470932.html
SOURCE Frost & Sullivan
Subscribe to our Free Newsletters!
Myomectomy is a surgery that is done to remove fibroids, which are non-cancerous growths of the ...
Rosacea is a chronic skin condition marked by facial redness and swelling especially around the ...
Immunotherapy is a type of treatment method that works by using certain components of a person's ...View All